Omaxe Ltd reported a standalone net profit of Rs 50.49 crore for Q2 FY27, turning around from a year-ago loss. However, consolidated results show a loss of Rs 25.14 crore. The company also faces a new SEBI order regarding minimum public shareholding compliance.
Omaxe Q2 FY27 Financial Performance
Standalone PAT: Rs 50.49 crore
Consolidated PAT: Rs (25.14) crore
Reader Takeaway: Standalone turnaround provides some relief, though consolidated losses and regulatory hurdles regarding public shareholding continue to weigh on sentiment.
What just happened
Omaxe Ltd announced its financial results for the quarter ended September 30, 2026. The real estate developer registered a standalone net profit of Rs 50.49 crore, a significant swing from the net loss of Rs 50.49 crore reported in the same period last year. Total standalone income reached Rs 310.40 crore, up from Rs 79.98 crore in the year-ago quarter. Consolidated results, however, remained in the red, with a net loss attributable to owners of Rs 25.14 crore, though this shows an improvement over the Rs 166.61 crore loss reported in the corresponding period of the previous year.
Why this matters
The divergence between standalone and consolidated performance indicates varying operational successes across the group's entities. While the standalone business shows signs of recovery in income and profitability, consolidated losses underscore the continued pressure on the broader corporate structure.
Regulatory and Legal Challenges
The company disclosed two significant legal updates in its filing. Most notably, on September 24, 2026, SEBI passed an order against Omaxe concerning non-compliance with Minimum Public Shareholding (MPS) requirements. The company is evaluating legal remedies and stated it does not expect a material impact on its financial position. Additionally, the Securities Appellate Tribunal (SAT) dismissed an appeal by the company regarding a previous SEBI order from July 2024, for which the firm has now filed a review application.
What to track next
Investors should monitor the firm's response to the September 2026 SEBI order and any subsequent regulatory directives. Furthermore, tracking whether the group can transition its consolidated performance toward net profitability will be critical for assessing long-term health.